Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

Background BI 853520 is a potent inhibitor of focal adhesion kinase and is currently under clinical development for the treatment of non-hematological malignancies. Objective The objective of this study was to evaluate the effect of food and liquid dispersion on the pharmacokinetics of BI 853520 in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2019-02, Vol.14 (1), p.67-74
Hauptverfasser:	Verheijen, Remy B., van der Biessen, Diane A. J., Hotte, Sebastien J., Siu, Lillian L., Spreafico, Anna, de Jonge, Maja J. A., Pronk, Linda C., De Vos, Filip Y. F. L., Schnell, David, Hirte, Hal W., Steeghs, Neeltje, Lolkema, Martijn P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Area Under Curve Bioequivalence Biomedicine Capsules Cross-Over Studies Female Focal Adhesion Kinase 1 - antagonists & inhibitors Food Food-Drug Interactions Humans Male Maximum Tolerated Dose Medicine Medicine & Public Health Middle Aged NCT NCT01335269 Neoplasm Metastasis Neoplasms - drug therapy Neoplasms - epidemiology Neoplasms - pathology Oncology Original Original Research Article Pharmacokinetics Plasma Prognosis Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Tablets - administration & dosage Targeted cancer therapy Therapeutic Equivalency Tissue Distribution
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!